Valuation: Silence Therapeutics plc

Market Cap 369M 496M 433M 400M 695M 47.76B 710M 4.78B 1.88B 23.39B 1.86B 1.82B 80.52B P/E 2026 *
-17.6x
P/E 2027 * -15.6x
Enterprise Value 222M 299M 261M 241M 419M 28.79B 428M 2.88B 1.13B 14.1B 1.12B 1.1B 48.54B EV / Sales 2026 *
89x
EV / Sales 2027 * 34.6x
Free-Float
69.36%
Yield 2026 *
-
Yield 2027 * -
1 day-3.85%
1 week+15.51%
Current month-4.37%
1 month+55.33%
3 months+39.44%
6 months+108.33%
Current year+72.70%
1 week 8.91
Extreme 8.91
11.19
1 month 6.93
Extreme 6.93
11.19
Current year 4.19
Extreme 4.19
11.19
1 year 4.19
Extreme 4.19
11.19
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 01/12/2025
Director of Finance/CFO 54 01/02/2022
Chief Tech/Sci/R&D Officer - 01/01/2021
Director TitleAgeSince
Director/Board Member 63 21/06/2018
Chairman 72 01/01/2004
Director/Board Member 65 05/05/2025
Date Insider Type Main position Quantity % Market Cap.
7/6/26 A Sell 865,112 0.6105%
1/2/26 A Free

Director

90,000 0.0635%
1/2/26 A Free

Chief Technology Officer

300,000 0.2117%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%+15.51%+68.81%+78.88% 496M
+3.90%-0.39%+376.72%+599.59% 39.58B
-1.70%+4.46%+7.46%+57.67% 34.69B
-2.01%-0.76%+26.35%-6.83% 34.42B
+0.06%+0.34%+2.32%+29.30% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 14.05B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average -0.21%+1.58%+205.94%+168.30% 20.67B
Weighted average by Cap. +0.23%+0.39%+171.16%+187.14%

Financials

2026 *2027 *
Net sales 2.5M 3.36M 2.94M 2.71M 4.71M 324M 4.81M 32.38M 12.74M 158M 12.62M 12.34M 545M 3.44M 4.63M 4.05M 3.74M 6.49M 446M 6.63M 44.64M 17.56M 218M 17.39M 17.01M 752M
Net income -50.43M -67.85M -59.29M -54.71M -95.05M -6.53B -97.16M -654M -257M -3.2B -255M -249M -11.02B -84.79M -114M -99.69M -91.99M -160M -10.99B -163M -1.1B -432M -5.38B -428M -419M -18.52B
Net Debt -146M -197M -172M -159M -276M -18.97B -282M -1.9B -747M -9.29B -740M -724M -31.99B -249M -336M -293M -271M -470M -32.32B -481M -3.23B -1.27B -15.83B -1.26B -1.23B -54.48B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
17/07/26 $10.50 -3.85% 277,230
16/07/26 $10.92 +4.50% 567,829
15/07/26 $10.45 +7.18% 791,970
14/07/26 $9.750 +4.95% 338,977
13/07/26 $9.290 +2.20% 233,638
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.50USD
Average target price
29.17USD
Spread / Average Target
+177.78%

Quarterly revenue - Rate of surprise